CytomX Therapeutics
CTMX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +313.6% in FY2025
Sean A. McCarthy, D. Phil. is the CEO of CytomX Therapeutics and was paid $4.7M in FY2025 (Dec), up 170%.
Pay$100 in the stock at the end of FY21 → $102
Executives3
See all- 1Sean A. McCarthy, D. Phil.Chief Executive Officer and Chairman of the Board of DirectorsFY2025
- 2Rachael LesterSenior Vice President and Chief Business OfficerFY2025
- 3Chris OgdenSenior Vice President, and Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCytomX Therapeutics paid its 3 named executives $8.5M in total in FY2025 (Dec). CEO Sean A. McCarthy, D. Phil. was paid $4.7M of that.
| Name | |||
|---|---|---|---|
| Sean A. McCarthy, D. Phil.Chief Executive Officer and Chairman of the Board of Directors | Not disclosed | ||
| Rachael LesterSenior Vice President and Chief Business Officer | Not disclosed | Not disclosed | |
| Chris OgdenSenior Vice President, and Chief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for CytomX Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Matthew P. YoungLead independent director · 10 yr on the boardIndependentAudit (Chair)—Paid as an executive
- James R. MeyersDirector · 7 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Halley GilbertDirector · 5 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
- Mani MohindruDirector · 5 yr on the boardIndependentAudit—Paid as an executive
- Alan Ashworth, Ph.D.Director · 4 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 16, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 4, 2024 | FY2023 |
| Annual report | 10-K | Mar 11, 2024 | FY2023 |
